• MPC, Lactate, and Dendritic Cell Histone Lactylation

  2026-08-16

  The 2025 reference study identifies mitochondrial pyruvate carrier (MPC) downregulation as a driver of lactate accumulation, histone lactylation, dendritic-cell dysfunction, and impaired CD8+ T-cell activity in colorectal cancer. Its findings connect tumor metabolic reprogramming with epigenetic and immune regulation, while suggesting that restoring MPC activity may improve anti-PD-1 responses.

• Q-VD(OMe)-OPh: Apoptosis Assay Workflows

  2026-08-15

  Q-VD(OMe)-OPh provides a practical way to separate caspase-dependent apoptosis from ferroptosis, autophagy, and other stress responses in combination-treatment experiments. Its broad activity and comparatively low nonspecific toxicity make it useful for cancer-cell assays, differentiation studies, and neuroprotection research when paired with orthogonal validation.

• NHE1, Olfr2, and Octanal in Atherosclerosis

  2026-08-14

  The reference study identifies macrophage NHE1 as a downstream effector linking octanal–Olfr2 sensing to calcium-dependent oxidative and inflammatory signaling in atherosclerosis. By combining ApoE−/− mice, RAW264.7 macrophages, pharmacological inhibition, RNA interference, and calcium chelation, it provides a mechanistic framework for interpreting NHE1 as a potential intervention point while highlighting the need for further validation in human disease.

• Okadaic acid (A4540): PP1/PP2A Workflow Guide

  2026-08-14

  Okadaic acid (A4540) provides a practical way to modulate serine/threonine phosphatase activity, with PP2A-predominant inhibition at low nanomolar concentrations and stronger PP1 inhibition at higher concentrations. It is suitable for controlled biochemical assays, phosphorylation studies, and carefully designed cell apoptosis induction workflows, but it should not be treated as a universal or fully selective phosphatase inhibitor.

• HCMV, UL38, and AKT Inactivation via IRS1

  2026-08-13

  The reference study identifies HCMV UL38 as a viral driver of mTORC1-dependent IRS1 destabilization, explaining how infected cells become less responsive to serum and fail to recruit AKT to signaling membranes. Its genetic, imaging, fractionation, and pharmacological experiments connect viral manipulation of host feedback signaling with a practical framework for studying phosphorylation-dependent pathways.

• Protein A/G Magnetic Co-IP/IP Kit for Ubiquitin Biology

  2026-08-13

  Discover how the Protein A/G Magnetic Co-IP/IP Kit can support rigorous protein-protein interaction analysis, using ubiquitin-regulated osteogenic signaling as a practical model. This article translates mechanistic findings into assay design, controls, and interpretation strategies.

• Cy5 NHS ester(Et): Practical Labeling Guide

  2026-08-12

  Cy5 NHS ester(Et) is an amine-reactive fluorescent dye for covalently tagging proteins, peptides, and other biomolecules for fluorescence-based detection. It is appropriate for aqueous or DMSO-assisted labeling workflows, but not ethanol-based protocols or long-term storage of prepared solutions.

• Angiotensin 1/2 (2-7) Assay Guide

  2026-08-12

  A scenario-based laboratory guide to using Angiotensin 1/2 (2-7), SKU A1050, in cell viability, proliferation, cytotoxicity, and mechanistic studies. It connects peptide identity, solubilization, controls, interpretation, and vendor selection to reproducible renin–angiotensin signaling research.

• Ferrostatin-1 (Fer-1) Assay Guide

  2026-08-11

  Ferrostatin-1 (Fer-1) helps distinguish lipid-peroxidation-driven ferroptosis from nonspecific cytotoxicity in melanocyte, cancer, neuronal, and glial models. This practical guide translates recent vitiligo research into dosing, controls, readouts, and troubleshooting decisions for more reproducible ferroptosis assays.

• Pepstatin A: Protease Control in Cell Assays

  2026-08-10

  Pepstatin A is an aspartic protease inhibitor for dissecting viral protein processing, cathepsin D biology, and osteoclast differentiation. This guide connects inhibitor selection and assay controls with mechanistic insights from a GABAAR trafficking study to improve interpretation of cell-based experiments.

• Angiotensin II: From GPCR Signal to Translational Model

  2026-08-09

  A mechanistic and strategic guide to using Angiotensin II as a controlled perturbation for hypertension, vascular remodeling, smooth muscle hypertrophy, aneurysm modeling, and carefully bounded RAS–viral entry research.

• Octenidine: Membrane Action to Translation

  2026-08-08

  A mechanistic and translational framework for using Octenidine dihydrochloride as a research benchmark, from membrane disruption and assay design to next-generation gemini antiseptic strategy.

• Dacarbazine In Vitro Cancer Response Workflows

  2026-08-07

  Use Dacarbazine as a mechanistic DNA-damage benchmark while separating growth arrest from true cell killing. This workflow combines fresh-solution handling, time-resolved viability assays, and orthogonal death measurements for more interpretable melanoma, lymphoma, and sarcoma models.

• Scutellarin Restores Endothelial Autophagy in Cardiac I/R vi

  2026-08-07

  This study reveals that scutellarin mitigates cardiac ischemia/reperfusion-induced endothelial dysfunction by upregulating cathepsin D and restoring autophagy–lysosomal function. The findings highlight cathepsin D as a pivotal mediator in vascular recovery and provide a mechanistic rationale for targeting aspartic proteases in endothelial protection.

• Camptothecin as a DNA Damage and Adaptive Mutation Probe

  2026-08-06

  Explore how Camptothecin, a potent topoisomerase I inhibitor, enables advanced studies of DNA damage, adaptive mutagenesis, and cell fate. This article uniquely connects prion-driven mutagenesis with Camptothecin's mechanistic utility in cancer and genome stability research.

16333 records 1/1089 page Next 12345 下5页 Last page